Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
Immunomodulatory drug (IMiD)
Pomalidomide
Pomalyst · POM
A later-generation IMiD usable across renal impairment, with tumor lysis as the main kidney risk.
MildImmunomodulatory drug (IMiD) · approved 2013
Multiple myeloma (relapsed/refractory)Kaposi sarcoma
Signature kidney injury
Prerenal / Hemodynamic AKI
Pomalidomide pharmacokinetics are not substantially altered by renal impairment - it is extensively metabolized hepatically, with <5% renal excretion of unchanged drug - and pooled trial data show a similar safety profile and dosing across renal-function subgroups, including dialysis. The principal renal hazard is tumor lysis syndrome (TLS), which is uncommon and case-level in myeloma.
Source: Siegel et al., Leuk Lymphoma 2016 (pooled renal-impairment analysis)
Mechanism of kidney injury
Direct nephrotoxicity is minimal; kidney injury is predominantly indirect. Rapid tumor cell death releases uric acid, potassium, and phosphate; uric-acid and calcium-phosphate crystals precipitate within distal tubules (intratubular obstruction) and hyperuricemia causes a prerenal/crystal-nephropathy AKI, particularly with high tumor burden or volume depletion.
Clinical presentation
Most patients maintain stable renal function. TLS presents with hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, and rising creatinine within days of starting therapy; oliguria can develop with crystal obstruction.
Onset
Tumor lysis typically within days of starting therapy in high-burden disease.
Reversibility
Reversible
Anticancer mechanism
Third-generation cereblon-binding immunomodulatory drug that degrades IKZF1/IKZF3, with antimyeloma, anti-angiogenic, and T/NK-cell immunostimulatory activity. Used in relapsed/refractory multiple myeloma, usually with dexamethasone, and in Kaposi sarcoma.
Management
Treat established TLS with aggressive isotonic hydration, rasburicase for hyperuricemia, and electrolyte correction; dialysis for refractory hyperkalemia, hyperphosphatemia, or oligoanuric AKI. Because pomalidomide is hepatically metabolized, it is generally usable in renal impairment without major PK-based dose change, though clinical monitoring remains important.
Risk factors
- High tumor burden / rapidly proliferative disease
- Pre-existing renal impairment
- Volume depletion
- Elevated baseline uric acid or LDH
Prevention
- Risk-stratify for TLS and give prophylaxis: hydration plus allopurinol (intermediate risk) or rasburicase (high risk)
- Maintain adequate hydration; avoid urine alkalinization (promotes calcium-phosphate deposition)
- Monitor electrolytes, uric acid, phosphate, and creatinine early in therapy
Note · Distinguished from lenalidomide by usability in renal impairment. Direct nephrotoxicity is not a defining feature; tumor lysis is the key renal concern.
Clinical depth
Renal dose adjustment
No starting-dose change is required for renal impairment, including severe CKD and dialysis (extensive hepatic metabolism). On hemodialysis, give pomalidomide after the dialysis session. Reduce dose for hepatic impairment and for hematologic toxicity.
Dialyzability & ESKD dosing
Pomalidomide is not appreciably removed by hemodialysis to a degree requiring supplemental dosing; administer the daily dose after dialysis on dialysis days. No dose reduction needed for ESKD.
Differential diagnosis
Distinguish TLS-related crystal nephropathy (hyperuricemia, hyperphosphatemia, urate/calcium-phosphate crystals) from prerenal azotemia (volume responsive) and from myeloma cast nephropathy (paraprotein, free light chains). The metabolic profile and timing within days of cytoreduction identify TLS.
Monitoring
- Uric acid, potassium, phosphate, calcium, and creatinine at initiation in high-burden disease
- CBC at least monthly
- Renal function periodically
Key trials & series
- Siegel et al. pooled analysis of pomalidomide-dexamethasone across renal-impairment subgroups
- Coiffier et al. evidence-based TLS management guidelines
Clinical pearls
- Pomalidomide is the IMiD of choice in significant renal impairment - no dose change and usable on dialysis, unlike lenalidomide.
- The kidney risk is the disease response (tumor lysis), not the drug itself - prophylax high-burden patients.
- Avoid urinary alkalinization in TLS; it favors calcium-phosphate precipitation.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Tubular Lumen
The urine flow path
Injury signatures
Prerenal / Hemodynamic AKIElectrolyte Wasting
Beyond the kidney
Class-level context for the major non-renal toxicities of immunomodulatory drug (imid)s.
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
- Venous thromboembolism
Hematologic
Cytopenias, thrombosis, TMA
- Myelosuppression
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
- Neuropathy (thalidomide)
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkPomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.Siegel DS et al. · Leuk Lymphoma 2016 · PMID 27267105Pooled trials showing similar safety/dosing of pomalidomide across moderate renal impairment.PMIDNew Agents in Multiple Myeloma: An Examination of Safety Profiles.Bringhen S et al. · Clin Lymphoma Myeloma Leuk 2017 · PMID 28601492Reviews myeloma-agent safety, noting pomalidomide PK is largely unaffected by renal impairment.PMIDTumor lysis syndrome in patients with light chain multiple myeloma: report of two cases.Chang H et al. · Chang Gung Med J 2011 · PMID 22490464Illustrates tumor lysis syndrome risk in myeloma treated with novel agents.PMIDGuidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.Coiffier B et al. · J Clin Oncol 2008 · PMID 18509186Foundational evidence-based TLS prophylaxis/management guideline (hydration, allopurinol, rasburicase; no alkalinization).PMIDNew drug toxicities in the onco-nephrology world.Perazella MA et al. · Kidney Int 2015 · PMID 25671763Onco-nephrology class context for novel-agent renal effects.PMIDPharmacological nephrotoxicity profile in a comprehensive cancer center: What changed in two decades and predictors for the need for haemodialysis and mortality.Ferreira A et al. · Nefrologia (Engl Ed) 2025 · PMID 40783302Cancer-center AKI series contextualizing drug-induced AKI in hematologic malignancy.
Related agents
Other agents sharing the same signature kidney injury.